Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone for prevention of relapse in schizophrenia
2021-002068-30Phase 3Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Lumateperone with Placebo (2 arms). Primary endpoint: Relapse during double-blind treatment period. Started Oct 2021; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2021-002068-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002068-30.